CAR-T cell therapy specialist Kite Pharma, now part of Gilead Sciences, has expanded its cell therapy...
Up To Date
Latest News
CAR-T cell developer bluebird bio Inc. has extended its potential US$1bn deal with cancer neoantigen TCR...
British drug maker AstraZeneca’s IL-5Ralpha blocker benralizumab did not reduce exacerbations significantly...
A research team headed by Jean-Christophe Leroux from ETH Zurüch has created the first-ever 3-D printed mouth...
Following weeks of negotiations and four rejected bids, British neurology and orphan drug giant Shire has...
Vas Narasimhan, the newly appointed CEO of Swiss pharma giant Novartis, introduced himself to the Swiss...
Share
